Free Trial

Adaptive Biotechnologies (ADPT) News Today

Adaptive Biotechnologies logo
$8.24 -0.18 (-2.14%)
Closing price 04:00 PM Eastern
Extended Trading
$8.50 +0.26 (+3.14%)
As of 07:33 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.
Adaptive Biotechnologies Co. stock logo
Adaptive Biotechnologies (NASDAQ:ADPT) Hits New 52-Week High - Here's Why
Adaptive Biotechnologies (NASDAQ:ADPT) Hits New 52-Week High - Here's What Happened
Adaptive Biotechnologies Co. stock logo
Charles Schwab Investment Management Inc. Acquires 39,831 Shares of Adaptive Biotechnologies Co. (NASDAQ:ADPT)
Charles Schwab Investment Management Inc. raised its holdings in shares of Adaptive Biotechnologies Co. (NASDAQ:ADPT - Free Report) by 4.3% in the 4th quarter, according to its most recent 13F filing with the SEC. The fund owned 956,574 shares of the company's stock after acquiring an additional 39
Adaptive Biotechnologies Co. stock logo
Adaptive Biotechnologies (NASDAQ:ADPT) Shares Gap Up - Here's What Happened
Adaptive Biotechnologies (NASDAQ:ADPT) Shares Gap Up - Should You Buy?
Adaptive Biotechnologies Co. stock logo
Adaptive Biotechnologies (NASDAQ:ADPT) Raised to "Buy" at The Goldman Sachs Group
The Goldman Sachs Group upgraded shares of Adaptive Biotechnologies from a "neutral" rating to a "buy" rating and set a $9.00 target price on the stock in a report on Friday.
Adaptive Biotechnologies Co. stock logo
Adaptive Biotechnologies (NASDAQ:ADPT) Trading Up 6.9% - Should You Buy?
Adaptive Biotechnologies (NASDAQ:ADPT) Trading 6.9% Higher - Still a Buy?
Adaptive Biotechnologies (ADPT) Gets a Buy from BTIG
Adaptive Biotechnologies Co. stock logo
Nikko Asset Management Americas Inc. Has $40.93 Million Holdings in Adaptive Biotechnologies Co. (NASDAQ:ADPT)
Nikko Asset Management Americas Inc. lessened its holdings in shares of Adaptive Biotechnologies Co. (NASDAQ:ADPT - Free Report) by 11.6% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 6,833,137 shares of the company's stock after
Adaptive Biotechnologies Co. stock logo
Adaptive Biotechnologies (NASDAQ:ADPT) Trading Down 6.1% After Insider Selling
Adaptive Biotechnologies (NASDAQ:ADPT) Stock Price Down 6.1% Following Insider Selling
Adaptive Biotechnologies Co. stock logo
Adaptive Biotechnologies Co. (NASDAQ:ADPT) Director Sells $70,500.00 in Stock
Adaptive Biotechnologies Co. (NASDAQ:ADPT - Get Free Report) Director Peter M. Neupert sold 10,000 shares of the stock in a transaction on Monday, March 10th. The stock was sold at an average price of $7.05, for a total transaction of $70,500.00. Following the transaction, the director now directly owns 224,690 shares in the company, valued at $1,584,064.50. The trade was a 4.26 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.
Adaptive Biotechnologies Co. stock logo
Insider Selling: Adaptive Biotechnologies Co. (NASDAQ:ADPT) Director Sells $402,270.00 in Stock
Adaptive Biotechnologies Co. (NASDAQ:ADPT - Get Free Report) Director Robert Hershberg sold 53,000 shares of the business's stock in a transaction that occurred on Wednesday, March 12th. The shares were sold at an average price of $7.59, for a total transaction of $402,270.00. Following the transaction, the director now owns 69,690 shares of the company's stock, valued at approximately $528,947.10. This represents a 43.20 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website.
Adaptive Biotechnologies Co. stock logo
Adaptive Biotechnologies (NASDAQ:ADPT) Trading Up 10.4% - Time to Buy?
Adaptive Biotechnologies (NASDAQ:ADPT) Trading 10.4% Higher - Still a Buy?
Adaptive Biotechnologies launches assay enhancements for clonoSeq
Adaptive Biotechnologies Co. stock logo
US Bancorp DE Sells 43,819 Shares of Adaptive Biotechnologies Co. (NASDAQ:ADPT)
US Bancorp DE lowered its holdings in Adaptive Biotechnologies Co. (NASDAQ:ADPT - Free Report) by 26.9% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 119,287 shares of the company's stock after selling 43,8
Adaptive Biotechnologies Co. stock logo
Essex Investment Management Co. LLC Cuts Stake in Adaptive Biotechnologies Co. (NASDAQ:ADPT)
Essex Investment Management Co. LLC reduced its holdings in shares of Adaptive Biotechnologies Co. (NASDAQ:ADPT - Free Report) by 12.9% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 625,838 shares of the
Adaptive Biotechnologies Co. stock logo
Adaptive Biotechnologies (NASDAQ:ADPT) Shares Down 6.5% After Insider Selling
Adaptive Biotechnologies (NASDAQ:ADPT) Shares Down 6.5% Following Insider Selling
Adaptive Biotechnologies Co. stock logo
Adaptive Biotechnologies Co. (NASDAQ:ADPT) CFO Sells $72,033.60 in Stock
Adaptive Biotechnologies Co. (NASDAQ:ADPT - Get Free Report) CFO Kyle Piskel sold 10,320 shares of the firm's stock in a transaction that occurred on Wednesday, March 5th. The shares were sold at an average price of $6.98, for a total value of $72,033.60. Following the completion of the transaction, the chief financial officer now owns 269,010 shares in the company, valued at approximately $1,877,689.80. This trade represents a 3.69 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.
Adaptive Biotechnologies Co. stock logo
Adaptive Biotechnologies Co. (NASDAQ:ADPT) Director Michelle Renee Griffin Sells 15,664 Shares
Adaptive Biotechnologies Co. (NASDAQ:ADPT - Get Free Report) Director Michelle Renee Griffin sold 15,664 shares of the company's stock in a transaction that occurred on Thursday, March 6th. The shares were sold at an average price of $7.94, for a total value of $124,372.16. Following the completion of the sale, the director now directly owns 51,685 shares in the company, valued at approximately $410,378.90. The trade was a 23.26 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink.
Adaptive Biotechnologies Co. stock logo
Francis Lo Sells 20,875 Shares of Adaptive Biotechnologies Co. (NASDAQ:ADPT) Stock
Adaptive Biotechnologies Co. (NASDAQ:ADPT - Get Free Report) insider Francis Lo sold 20,875 shares of Adaptive Biotechnologies stock in a transaction that occurred on Wednesday, March 5th. The shares were sold at an average price of $6.99, for a total transaction of $145,916.25. Following the sale, the insider now directly owns 332,846 shares in the company, valued at approximately $2,326,593.54. The trade was a 5.90 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website.
Adaptive Biotechnologies Co. stock logo
Adaptive Biotechnologies Co. (NASDAQ:ADPT) COO Julie Rubinstein Sells 59,505 Shares
Adaptive Biotechnologies Co. (NASDAQ:ADPT - Get Free Report) COO Julie Rubinstein sold 59,505 shares of the business's stock in a transaction that occurred on Wednesday, March 5th. The shares were sold at an average price of $6.98, for a total transaction of $415,344.90. Following the completion of the transaction, the chief operating officer now directly owns 588,249 shares of the company's stock, valued at approximately $4,105,978.02. This represents a 9.19 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.
Adaptive Biotechnologies Co. stock logo
Adaptive Biotechnologies Co. (NASDAQ:ADPT) CEO Sells $819,109.98 in Stock
Adaptive Biotechnologies Co. (NASDAQ:ADPT - Get Free Report) CEO Chad M. Robins sold 117,351 shares of the business's stock in a transaction on Wednesday, March 5th. The stock was sold at an average price of $6.98, for a total value of $819,109.98. Following the transaction, the chief executive officer now directly owns 2,814,350 shares of the company's stock, valued at $19,644,163. The trade was a 4.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.
Adaptive Biotechnologies Co. stock logo
Principal Financial Group Inc. Purchases Shares of 143,444 Adaptive Biotechnologies Co. (NASDAQ:ADPT)
Principal Financial Group Inc. acquired a new position in Adaptive Biotechnologies Co. (NASDAQ:ADPT - Free Report) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 143,444 shares of the company's stock, valued at app
Adaptive Biotechnologies Co. stock logo
Adaptive Biotechnologies (NASDAQ:ADPT) Shares Gap Down - Time to Sell?
Adaptive Biotechnologies (NASDAQ:ADPT) Shares Gap Down - What's Next?
Adaptive Biotechnologies Co. stock logo
Private Advisor Group LLC Makes New $264,000 Investment in Adaptive Biotechnologies Co. (NASDAQ:ADPT)
Private Advisor Group LLC purchased a new stake in Adaptive Biotechnologies Co. (NASDAQ:ADPT - Free Report) in the 4th quarter, according to its most recent disclosure with the SEC. The fund purchased 43,977 shares of the company's stock, valued at approximately $264,000. A number of other institut
Adaptive Biotechnologies Co. stock logo
ARK Investment Management LLC Sells 2,177,060 Shares of Adaptive Biotechnologies Co. (NASDAQ:ADPT)
ARK Investment Management LLC reduced its stake in Adaptive Biotechnologies Co. (NASDAQ:ADPT - Free Report) by 18.8% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 9,424,074 shares of the company's stock after selling 2,177,060 shares
Adaptive Biotechnologies Co. stock logo
Chad M. Robins Sells 99,107 Shares of Adaptive Biotechnologies Co. (NASDAQ:ADPT) Stock
Adaptive Biotechnologies Co. (NASDAQ:ADPT - Get Free Report) CEO Chad M. Robins sold 99,107 shares of the stock in a transaction on Thursday, February 20th. The shares were sold at an average price of $8.44, for a total value of $836,463.08. Following the sale, the chief executive officer now owns 2,576,701 shares of the company's stock, valued at approximately $21,747,356.44. This represents a 3.70 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website.
Adaptive Biotechnologies Co. stock logo
Adaptive Biotechnologies (NASDAQ:ADPT) Earns "Overweight" Rating from Piper Sandler
Piper Sandler restated an "overweight" rating and issued a $11.00 price target (up from $7.00) on shares of Adaptive Biotechnologies in a research note on Thursday.
Adaptive Biotechnologies Co. stock logo
Adaptive Biotechnologies Co. (NASDAQ:ADPT) CEO Chad M. Robins Sells 158,921 Shares
Adaptive Biotechnologies Co. (NASDAQ:ADPT - Get Free Report) CEO Chad M. Robins sold 158,921 shares of the firm's stock in a transaction dated Friday, February 14th. The stock was sold at an average price of $8.46, for a total transaction of $1,344,471.66. Following the completion of the transaction, the chief executive officer now directly owns 2,576,701 shares in the company, valued at $21,798,890.46. This represents a 5.81 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.
Adaptive Biotechnologies Co. stock logo
Chad M. Robins Sells 211,160 Shares of Adaptive Biotechnologies Co. (NASDAQ:ADPT) Stock
Adaptive Biotechnologies Co. (NASDAQ:ADPT - Get Free Report) CEO Chad M. Robins sold 211,160 shares of the business's stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $8.50, for a total value of $1,794,860.00. Following the completion of the transaction, the chief executive officer now owns 2,576,701 shares in the company, valued at approximately $21,901,958.50. This trade represents a 7.57 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink.
Adaptive Biotechnologies Co. stock logo
Adaptive Biotechnologies Co. (NASDAQ:ADPT) Shares Sold by DDD Partners LLC
DDD Partners LLC lessened its holdings in Adaptive Biotechnologies Co. (NASDAQ:ADPT - Free Report) by 91.6% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 64,747 shares of the company's stock after
Adaptive Biotechnologies Co. stock logo
Adaptive Biotechnologies (NASDAQ:ADPT) Shares Up 7.9% Following Analyst Upgrade
Adaptive Biotechnologies (NASDAQ:ADPT) Shares Up 7.9% Following Analyst Upgrade
Adaptive Biotechnologies Co. stock logo
Adaptive Biotechnologies (NASDAQ:ADPT) Reaches New 1-Year High After Analyst Upgrade
Adaptive Biotechnologies (NASDAQ:ADPT) Sets New 52-Week High Following Analyst Upgrade
Adaptive Biotechnologies Co. stock logo
Scotiabank Issues Positive Forecast for Adaptive Biotechnologies (NASDAQ:ADPT) Stock Price
Scotiabank increased their target price on Adaptive Biotechnologies from $10.00 to $12.00 and gave the stock a "sector outperform" rating in a research report on Thursday.
Adaptive Biotechnologies Co. stock logo
Legato Capital Management LLC Has $1.11 Million Holdings in Adaptive Biotechnologies Co. (NASDAQ:ADPT)
Legato Capital Management LLC cut its holdings in shares of Adaptive Biotechnologies Co. (NASDAQ:ADPT - Free Report) by 23.5% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 184,668 shares of the com
Remove Ads
Get Adaptive Biotechnologies News Delivered to You Automatically

Sign up to receive the latest news and ratings for ADPT and its competitors with MarketBeat's FREE daily newsletter.

ADPT Media Mentions By Week

ADPT Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

ADPT
News Sentiment

0.48

0.89

Average
Medical
News Sentiment

ADPT News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

ADPT Articles
This Week

14

4

ADPT Articles
Average Week

Remove Ads
Get Adaptive Biotechnologies News Delivered to You Automatically

Sign up to receive the latest news and ratings for ADPT and its competitors with MarketBeat's FREE daily newsletter.


Related Companies and Tools


This page (NASDAQ:ADPT) was last updated on 3/26/2025 by MarketBeat.com Staff
From Our Partners